 CHICAGO--BUSINESS WIRE--Xeris Pharmaceuticals, Inc. Nasdaq: XERS, a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on February 24, 2021, the Compensation Committee of Xeris Board of Directors granted non-qualified stock options for an aggregate of 5,000 shares, and restricted stock units for an aggregate of 9,500 shares, of its common stock to 3 new employe 